Top 5 Electric Utility Companies To Own For 2014

Concerns over future Fed action are causing some turmoil in the market and DASH Financial's Michael Khouw discusses what he sees as the longer-term implications.

SPEAKER 1:  My guest today is Mike Khow.  Hi Mike and thanks for joining me.

MICHAEL:  Thanks for having me.

SPEAKER 1:  You know we’ve had a really good run in the market and some people are saying that the whole idea of tapering is what recently brought the market down 225 points in one day.  Everyone thinks oh my gosh, 225 points, but in reality, percentage wise, it really isn’t that bad.  I mean, where do we go from here?  I mean, do you think this tapering concept has kind of been hovering over us as a black cloud for the last few months?  Do you think that’s going to keep investors out of the market now?

MICHAEL:  Well, I think it’s definitely a cause for concern; not just among individual investors, but institutional investors.  Think about this; QE was the biggest justification for some of the largest bowls in the market over the course of the last couple of years.  I’m talking about guys like David Tepper and other who said that it was foolish to think that the market could do anything but go up, all right.  A lot of people think of QE as printing money, okay, and while there is an element of truth to that concept, what we really have to understand is that the reason the Fed was doing this was when the credit bubble collapsed, essentially, the money supply decreased because there was a huge amount of non-inter financial lending that was built into it, and the way to think about that, there’s a multiplier effect.

Top 5 High Tech Companies To Buy For 2015: Market Vectors Poland ETF (PLND)

Market Vectors Poland ETF (the Fund) seeks to replicate the price and yield performance of the Market Vectors Poland Index (the Index). The Index is a diversified index consisting of at least 25 companies either headquartered in Poland or deriving at least 50% of their revenues from Poland. It invest in sectors, such as financials, energy, industrials, consumer staples, telecomm services, materials, consumer discretionary, utilities, information technology and healthcare. The Fund�� investment advisor is Van Eck Associates Corporation. Advisors' Opinion:

• [By Benjamin Shepherd]

  Market Vectors Poland (NYSE: PLND) is a great exchange traded fund (ETF) play on the continued strength of the Polish economy.
  
  Financial services figure prominently in the ETF�� holdings at 44 percent of assets, but that�� lower than other competing products and largely reflective of the major role the financial sector plays in Poland�� economy. More than 23 percent of assets are allocated to basic materials and energy due to the country�� resource wealth.
  
  The ETF is also relatively cheap with an expense ratio of just 0.61 percent. It also offers the added benefit of a nearly 3.2 percent yield, thanks to the tradition of Polish stocks paying stable dividends.
  
  What�� more, the fund is inexpensive in terms of valuation because it price has been depressed by the ongoing crisis in Ukraine. Both countries have historically been Russian satellites, but Poland was quick to integrate itself with Western Europe after the country�� communist government fell in 1989. As a result, it enjoys the diplomatic cover of the EU and the military protection of the North Atlantic Treaty Organization, making it unlikely that Russia will interfere in the country�� politics.
  
  Despite those protections, the fund�� price-to-forward-earnings ratio has fallen from about 19 to just 14 over the past few weeks and shares are now trading at book value. Shares are also trading at just 0.58 times sales, a substantial discount to the fund�� historical valuation largely due to regional concerns.

Top 5 Electric Utility Companies To Own For 2014: Regeneron Pharmaceuticals Inc.(REGN)

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.

Advisors' Opinion:

• [By Brian Orelli]

  Sanofi and Regeneron Pharmaceuticals (NASDAQ: REGN  ) have one that's codenamed REGN727/SAR236553. In a phase 2 trial, it reduced bad LDL cholesterol by up to 67.9% compared with a 10.7% reduction in patients receiving placebo.

• [By Mani]

  The safety and tolerability profile for Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) anti-PCSK9 antibody Alirocumab is in good stead against Amgen's AMG145, and supports upside potential of the Regeneron antibody in the multi-billion dollar market for cholesterol lowering drugs.

• [By Hilary Kramer]

  I��e long been a fan of Regeneron (REGN), and have recommended it in recent years to my own investment newsletter subscribers.� The company�� shares have risen by roughly 70% in the past year, besting the market and pacing the 66% rise in 2013 for the biotech sector.� At a recent $290 a share, REGN should outperform the market in the near term, rising double digits to the mid $300 level.

• [By Ben Levisohn]

  This year, Celgene has dropped 9.9%, even as other giant biotech companies like Biogen Idec (BIIB), Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN) has gained 7% or more. Even the SPDR S&P Biotech ETF (XBI) has managed to stay above water despite big March losses.

Top 5 Electric Utility Companies To Own For 2014: Griffin Land & Nurseries Inc.(GRIF)

Griffin Land & Nurseries, Inc., together with its subsidiaries, engages in real estate and landscape nursery businesses in the United States. The company?s real estate business consists of the ownership, construction, leasing, and management of commercial and industrial properties, as well as the development of residential subdivisions on real estate owned by it in Connecticut, Massachusetts, and Pennsylvania. Its landscape nursery business comprises the growing of containerized plants for sale principally to independent retail garden centers, rewholesalers, mass merchandisers, home centers, and landscape contractors. Griffin Land & Nurseries, Inc. was founded in 1970 and is based in New York City, New York.

Advisors' Opinion:

• [By Dividends4Life]

  Memberships and Peers: ADM is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: Bunge Limited (BG) with a 1.6% yield, Ingredion Incorporated (INGR) with a 2.4% yield and Griffin Land & Nurseries Inc. (GRIF) with a 0.7% yield.

Top 5 Electric Utility Companies To Own For 2014: Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs; and proprietary branded pharmaceuticals in various therapeutic categories and active pharmaceutical ingredients worldwide. The company?s provides generic drug portfolio of approximately 1,450 molecules and a direct presence in 60 countries. It offers generic pharmaceutical products in a range of dosage forms, such as tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The company sells its generic injectable products to hospitals, clinics, and other institutional channels, primarily in the United States and Europe, as well as in Latin America and eastern Europe. Its branded products include Copaxone to treat multiple sclerosis; and Azilect to treat Parkinson?s disease, as well as biosimilars, respiratory, and women?s health products. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

Advisors' Opinion:

• [By Pharma Reports]

  Teva Pharmaceutical Industries (TEVA), the world's leading generic drug maker with global sales of over $20 billion and a product portfolio of more than 1,000 molecules, just announced that it is accelerating its cost- reduction program and reducing its global work force by 10%.

• [By Jayson Derrick]

  Analysts at Barclays upgraded Teva Pharmaceuticals (NASDAQ: TEVA) to Overweight from Equal-weight with a price target raised to $65 from a previous $42. Shares lost 1.10 percent, closing at $49.27.

• [By GuruFocus]

  George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated

• [By Maxx Chatsko]

  Reasons for pessimism?
  I may be digging a little bit here -- I admit it's tough to come up with negatives -- but Friday's announcement invalidating several Teva (NYSE: TEVA  ) patents for multiple sclerosis drug Copaxone could shake up the market quite a bit. Could the emergence of two cheap generics from Momenta and Mylan in the first half of next year take some steam out of Tecfidera's rise? I can't see it being good news for either Teva or Biogen, but I'm not sure it's a death sentence, either.